blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1863920

EP1863920 - METHOD FOR ISOLATION OF RECOMBINANTLY PRODUCED PROTEINS [Right-click to bookmark this link]
Former [2007/50]METHOD FOR IMPROVED ISOLATION OF RECOMBINANTLY PRODUCED PROTEINS
[2013/44]
StatusPatent revoked
Status updated on  06.11.2019
Database last updated on 26.06.2024
Most recent event   Tooltip08.11.2019Revocation of patentpublished on 11.12.2019  [2019/50]
Applicant(s)For all designated states
Octapharma AG
Seidenstrasse 2
8853 Lachen / CH
[2007/50]
Inventor(s)01 / WINGE, Stefan
Langhalsvägen 17, 2tr
S-12050 Arsta / SE
 [2007/50]
Representative(s)Ullrich & Naumann PartG mbB
Schneidmühlstrasse 21
69115 Heidelberg / DE
[N/P]
Former [2010/15]von Kreisler Selting Werner
Deichmannhaus am Dom Bahnhofsvorplatz 1
50667 Köln / DE
Former [2009/47]Helbing, Jörg
Patentanwälte von Kreisler Selting Werner Postfach 10 22 41
50462 Köln / DE
Former [2007/50]Helbing, Jörg
Von Kreisler Selting Werner Postfach 10 22 41
50462 Köln / DE
Application number, filing date06725404.529.03.2006
[2007/50]
WO2006EP61148
Priority number, dateEP2005010247529.03.2005         Original published format: EP 05102475
[2007/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006103258
Date:05.10.2006
Language:EN
[2006/40]
Type: A1 Application with search report 
No.:EP1863920
Date:12.12.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 05.10.2006 takes the place of the publication of the European patent application.
[2007/50]
Type: B1 Patent specification 
No.:EP1863920
Date:01.12.2010
Language:EN
[2010/48]
Search report(s)International search report - published on:EP05.10.2006
ClassificationIPC:C12P21/02, C07K14/755
[2007/50]
CPC:
C07K14/755 (EP,US); C12P21/00 (US); A61P7/02 (EP);
B01D15/08 (EP,US); C12N15/79 (US); C12N5/0018 (US);
C12N9/644 (EP,US); C12N9/647 (EP,US); C12P21/02 (EP,US);
C12Y304/21022 (EP,US); Y02P20/52 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/50]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
YUNot yet paid
TitleGerman:VERFAHREN ZUR ISOLIERUNG VON REKOMBINANT HERGESTELLTEN PROTEINEN[2013/44]
English:METHOD FOR ISOLATION OF RECOMBINANTLY PRODUCED PROTEINS[2013/44]
French:PROCÉDÉ POUR L'ISOLATION DE PROTÉINES RECOMBINANTES[2013/44]
Former [2007/50]VERFAHREN ZUR VERBESSERTEN ISOLIERUNG REKOMBINANT PRODUZIERTER PROTEINE
Former [2007/50]METHOD FOR IMPROVED ISOLATION OF RECOMBINANTLY PRODUCED PROTEINS
Former [2007/50]PROCÉDÉ D'ISOLATION AMELIORÉE DES PROTÉINES DE RECOMBINAISON
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase09.10.2007National basic fee paid 
09.10.2007Designation fee(s) paid 
09.10.2007Examination fee paid 
Examination procedure29.01.2007Request for preliminary examination filed
International Preliminary Examining Authority: EP
09.10.2007Examination requested  [2007/50]
13.03.2008Despatch of a communication from the examining division (Time limit: M06)
22.09.2008Reply to a communication from the examining division
13.04.2010Date of oral proceedings
20.05.2010Date of oral proceedings
04.06.2010Minutes of oral proceedings despatched
11.06.2010Communication of intention to grant the patent
19.10.2010Fee for grant paid
19.10.2010Fee for publishing/printing paid
Divisional application(s)EP10181019.0  / EP2258860
EP18185708.7  / EP3467116
Opposition(s)Opponent(s)01  23.08.2011  13.09.2011  ADMISSIBLE
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd / DK
Opponent's representative
Goodfellow, Hugh Robin
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 [N/P]
Former [2011/39]
Opponent(s)01  23.08.2011   
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd / DK
Opponent's representative
Goodfellow, Hugh Robin
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
10.10.2011Invitation to proprietor to file observations on the notice of opposition
20.04.2012Reply of patent proprietor to notice(s) of opposition
18.09.2013Date of oral proceedings
15.01.2014Despatch of interlocutory decision in opposition
15.01.2014Despatch of minutes of oral proceedings
24.07.2019Legal effect of revocation of patent [2019/50]
11.09.2019Despatch of communication that the patent will be revoked
Appeal following opposition25.03.2014Appeal received No.  T0688/14
26.05.2014Statement of grounds filed
24.07.2019Result of appeal procedure: revocation of the patent
25.03.2014Appeal received No.  T0688/14
23.05.2014Statement of grounds filed
24.07.2019Result of appeal procedure: revocation of the patent
24.07.2019Date of oral proceedings
02.08.2019Minutes of the oral proceedings despatched
Fees paidRenewal fee
18.03.2008Renewal fee patent year 03
25.03.2009Renewal fee patent year 04
23.03.2010Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
RO29.03.2013
CZ29.03.2014
IE29.03.2014
PL29.03.2014
SK29.03.2014
HU30.03.2014
SI30.03.2014
BE31.03.2014
PT29.09.2014
BG08.08.2017
[2019/10]
Former [2017/41]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
IE29.03.2014
PL29.03.2014
SK29.03.2014
HU30.03.2014
SI30.03.2014
BE31.03.2014
PT29.09.2014
Former [2015/24]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
IE29.03.2014
PL29.03.2014
SK29.03.2014
HU30.03.2014
SI30.03.2014
PT29.09.2014
Former [2015/14]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
IE29.03.2014
SK29.03.2014
HU30.03.2014
SI30.03.2014
PT29.09.2014
Former [2015/12]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
IE29.03.2014
SK29.03.2014
HU30.03.2014
PT29.09.2014
Former [2015/10]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
IE29.03.2014
SK29.03.2014
PT29.09.2014
Former [2015/07]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
IE29.03.2014
PT29.09.2014
Former [2015/02]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
PT29.09.2014
Former [2014/48]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
CZ29.03.2014
Former [2014/38]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
BG31.03.2012
RO29.03.2013
Former [2014/11]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
LU29.03.2011
MC31.03.2011
IS01.04.2011
GR04.10.2011
RO29.03.2013
Former [2011/38]CY01.12.2010
EE01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
IS01.04.2011
Former [2011/30]CY01.12.2010
FI01.12.2010
LT01.12.2010
LV01.12.2010
Former [2011/19]LT01.12.2010
Cited inInternational search[XD]  - MOUNIER CARINE M ET AL, "Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A2 occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2-alpha", JOURNAL OF BIOLOGICAL CHEMISTRY, (20040611), vol. 279, no. 24, ISSN 0021-9258, pages 25024 - 25038, XP002351312 [XD] 1-12 * section "Extraction of cell surface hGIIA with salt"; page 25026, column L * * page 25208, column L, paragraph 2 * * page 25208, column R, paragraph 3 * * page 25031, column R, paragraph L * * figure 1 *

DOI:   http://dx.doi.org/10.1074/jbc.M313019200
 [X]  - MOUNIER CARINE M ET AL, "SUPPLEMENTARY MATERIAL: Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A2 occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A2-alpha", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 24, ISSN 0021-9258, (20040611), pages 25024 - 25038, URL: http://www.jbc.org/cgi/data/M313019200/DC1/1, (20051021), XP002351313 [X] 1-12 * figure 2S *

DOI:   http://dx.doi.org/10.1074/jbc.M313019200
 [XD]  - VAANDRAGER ARIE B ET AL, "N-terminal myristoylation is required for membrane localization of cGMP-dependent protein kinase type II", JOURNAL OF BIOLOGICAL CHEMISTRY, (1996), vol. 271, no. 12, ISSN 0021-9258, pages 7025 - 7029, XP002351314 [XD] 1-12 * page 7026, column L *

DOI:   http://dx.doi.org/10.1074/jbc.271.12.7025
 [XD]  - ZUBER MICHAEL E ET AL, "Cysteine-rich FGF receptor regulates intracellular FGF-1 and FGF-2 levels", JOURNAL OF CELLULAR PHYSIOLOGY, (1997), vol. 170, no. 3, ISSN 0021-9541, pages 217 - 227, XP002351315 [XD] 1-12 * figure 2 * * page 218, column R, paragraph L *

DOI:   http://dx.doi.org/10.1002/(SICI)1097-4652(199703)170:3<217::AID-JCP1>3.0.CO;2-R
 [X]  - BOEDEKER B G D, "Production processes of licensed recombinant factor VIII preparations", SEMINARS IN THROMBOSIS AND HEMOSTASIS, STUTTGART, DE, (2001), vol. 27, no. 4, ISSN 0094-6176, pages 385 - 394, XP002263524 [X] 10-12 * the whole document *

DOI:   http://dx.doi.org/10.1055/s-2001-16891
 [A]  - SPIEGEL P C ET AL, "Disruption of Protein-Membrane Binding and Identification of Small-Molecule Inhibitors of Coagulation Factor VIII", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, (200410), vol. 11, no. 10, ISSN 1074-5521, pages 1413 - 1422, XP004601875 [A] * the whole document *

DOI:   http://dx.doi.org/10.1016/j.chembiol.2004.08.006
 [A]  - FAY PHILIP J ET AL, "Factor VIIIa cofactor activity shows enhanced ionic strength sensitivity in the absence of phospholipid", BIOCHIMICA ET BIOPHYSICA ACTA, (20010709), vol. 1548, no. 1, ISSN 0006-3002, pages 159 - 168, XP002351316 [A] * the whole document *
 [A]  - "N6658 NUTRIENT MIXTURE F12 (HAM) 1X LIQUID WITH L-GLUTAMINE AND SODIUM BICARBONATE", URL: http://www.sigmaaldrich.com/sigma/formulation/n6658for.pdf, (20051027), XP002351366 [A] * the whole document *
Examination   - Kolind M.P. et al., "The B-domain of Factor VIII reduces cell membrane attachment to host cells under serumfree conditions", J. Biotechnol., doi:10.1016/j.jbiotec.2010.04.010, (201005), URL: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T3C-4YYXJGB-3-C&_cdi=4943&_user=987766&_pii=S0168165610001951&_orig=search&_coverDate=04%2F30%2F2010&_sk=999999999&view=c&wchp=dGLbVzb-zSkzS&md5=3bf1bc5605a46b082425c41e1c6c1a22&ie=/sdarticle.pdf
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.